In addition to ibrutinib, individuals with M-CLL, devoid of TP53 aberrations and suit more than enough to tolerate FCR therapy, may still be good candidates for that latter, Using the benefit staying this therapy can be accomplished in six months when ibrutinib have to be taken indefinitely. This option would be specifically useful for non-complian